company background image
6621 logo

UniPharma TPEX:6621 Stock Report

Last Price

NT$14.00

Market Cap

NT$497.0m

7D

-0.7%

1Y

-33.0%

Updated

26 Mar, 2024

Data

Company Financials

6621 Stock Overview

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan.

6621 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

UniPharma Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UniPharma
Historical stock prices
Current Share PriceNT$14.00
52 Week HighNT$24.75
52 Week LowNT$12.00
Beta0.61
1 Month Change5.66%
3 Month Change-6.35%
1 Year Change-33.01%
3 Year Change0%
5 Year Change11.91%
Change since IPO-45.95%

Recent News & Updates

Recent updates

Shareholder Returns

6621TW HealthcareTW Market
7D-0.7%0.5%1.5%
1Y-33.0%-2.4%26.1%

Return vs Industry: 6621 underperformed the TW Healthcare industry which returned -2.4% over the past year.

Return vs Market: 6621 underperformed the TW Market which returned 26.1% over the past year.

Price Volatility

Is 6621's price volatile compared to industry and market?
6621 volatility
6621 Average Weekly Movement4.2%
Healthcare Industry Average Movement3.9%
Market Average Movement4.2%
10% most volatile stocks in TW Market8.0%
10% least volatile stocks in TW Market1.9%

Stable Share Price: 6621 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6621's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aYu-Shan Wanghttps://www.uni-pharma.com

UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. The company provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. It offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services.

UniPharma Co., Ltd. Fundamentals Summary

How do UniPharma's earnings and revenue compare to its market cap?
6621 fundamental statistics
Market capNT$497.01m
Earnings (TTM)-NT$14.14m
Revenue (TTM)NT$124.29m

4.0x

P/S Ratio

-35.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6621 income statement (TTM)
RevenueNT$124.29m
Cost of RevenueNT$54.14m
Gross ProfitNT$70.15m
Other ExpensesNT$84.29m
Earnings-NT$14.14m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin56.44%
Net Profit Margin-11.38%
Debt/Equity Ratio0%

How did 6621 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.